Vectical Receives Expanded Plaque Psoriasis Indication

July 24, 2020 – The U.S. FDA has approved an expanded indication for VecticalTM (calcitriol) topical ointment, manufactured by Galderma Laboratories, to treat mild to moderate plaque psoriasis in patients who are at least two years of age. Previously, the drug was only approved for use in patients who are at least 18 years old.

Plaque psoriasis is an autoimmune condition that causes excessively rapid production of new skin cells. This can lead to thickened, cracked, scaly skin as well as itching, skin discoloration, and cracked and bleeding skin. Vectical works to treat the disease by slowing the rate of skin cell production.

Under the recommended dosing, Vectical should be applied to affected areas twice daily. The maximum weekly dose should not exceed 200g in patients seven or older, or 100g in patients 2-6 years of age.

Vectical first received FDA approval in 2009.